Cutaneous Adverse Events Following Nemolizumab Administration: A Review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin conditions involving immune dysregulation and mediators like IL-4, IL-13, and IL-31.
• Nemolizumab, an IL-31 receptor A inhibitor, is approved for AD and PN treatment, showing efficacy in reducing pruritus and skin symptoms.

Purpose of the Study:

• To review cutaneous adverse events associated with nemolizumab therapy.
• To explore potential mechanisms and identify knowledge gaps in managing these reactions.

Main Methods:

• Literature review of clinical trials and practice observations regarding nemolizumab use.
• Analysis of reported cutaneous reactions and proposed underlying pathophysiological mechanisms.

Main Results:

• Nemolizumab treatment can lead to various skin reactions, including psoriasiform eruptions, AD exacerbation, bullous pemphigoid, drug-induced eruptions, and fungal infections.
• Observed reactions may stem from T-cell activation, hapten-induced immune responses, or altered cytokine balance (e.g., increased IL-4/IL-13).

Conclusions:

• Cutaneous adverse events are a clinical consideration for nemolizumab therapy in AD and PN.
• The exact mechanisms and risk factors for these reactions require further investigation.
• Development of standardized management guidelines and continued research are crucial for optimizing nemolizumab treatment and patient care.